Researchers at UCLA’s Jonsson Comprehensive Cancer Center and collaborating organizations report successful results from an experimental cancer-detection system that appears to have overcome some of the challenges of the “liquid biopsy” in a novel, cost-effective way.
Retinoblastoma is a cancer of the eye that occurs in infants and toddlers and can lead to loss of vision, loss of one or both eyes, and even death. Unlike most tumors, these cannot be biopsied because of the risk of spreading cancer to the rest of the body. In 2017, Jesse Berry, MD, surgeon and ocular oncologist at Children’s Hospital Los Angeles, discovered that fluid removed from the eye during treatment of retinoblastoma contained tumor DNA and functioned as a liquid biopsy—providing information about the tumor and opening the door to earlier diagnosis and treatment.
A multi-institutional, international study, led by researchers at the Johns Hopkins Kimmel Cancer Center and WEHI in Melbourne, Australia, found that testing for ctDNA after surgery and directing chemotherapy to ctDNA-positive patients reduced the use of chemotherapy overall without compromising recurrence-free survival.
Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure. Their study was published in the Journal of Experimental & Clinical Cancer Research in June.
Two studies led by Washington University School of Medicine in St. Louis describe the potential of liquid biopsies to identify and track tumor growth in two very different cancers: bladder cancer and peripheral nerve tumors.
A team of researchers from the NUS Department of Biomedical Engineering and Institute for Health Innovation & Technology has developed a novel blood test called ExoSCOPE that could tell doctors whether cancer treatment is working for a patient, within 24 hours after the treatment. This will enable doctors to customise the treatment plan to improve patients’ chances of recovery.
A new study from Washington University School of Medicine in St. Louis demonstrates that a liquid biopsy examining blood or urine can help gauge the effectiveness of therapy for colorectal cancer that has just begun to spread beyond the original tumor. Such a biopsy can detect lingering disease and could serve as a guide for deciding whether a patient should undergo further treatments.
The Cancer Research Institute (CRI) and The Mark Foundation for Cancer Research have launched a clinical trial that aims to demonstrate the utility of a novel, ultra-sensitive biomarker-directed blood test, or liquid biopsy, in assessing cancer patient responses to immunotherapy.
New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines coverage trends for circulating tumor DNA testing, also known as gene sequencing of ctDNA or “liquid biopsies.” The researchers found coverage rate rose from 0% to 38% in three years. The policies also increased in scope from 2017-2019, going from one cancer type to 12.
A novel liquid biopsy method can detect kidney cancers with high accuracy, including small, localized tumors which are often curable but for which no early detection method exists, say scientists from Dana-Farber Cancer Institute.
The report in Nature Medicine suggests that if validated in larger trials and applied widely, the non-invasive test could find more early kidney cancers when they haven’t spread, thus reducing the mortality of the disease.
Results from a first-of-its-kind study of a multicancer blood test in more than 9,900 women with no evidence or history of cancer showed the liquid biopsy test safely detected 26 undiagnosed cancers, enabling potentially curative treatment.
From a simple blood draw, microbial DNA may reveal who has cancer and which type, even at early stages
A study at The University of Texas MD Anderson Cancer Center found that chemotherapy results in increased heterogeneity within small cell lung cancer, leading to the evolution of multiple resistance mechanisms.
A team of researchers from the National University of Singapore has developed a personalised assessment tool which can detect the incidence of cancer, predict patient survivability and determine patient suitability for immunotherapy cancer treatment.
A blood test that measures the amount of cell-free DNA (cfDNA) in the bloodstream – called a liquid biopsy – correlates with how patients will progress after they are diagnosed with glioblastoma (GBM), the deadliest and most common primary brain tumor in adults
Memorial Sloan Kettering Cancer Center (MSK) announced that the New York State Department of Health has issued an approval for a new molecular assay called Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS). MSK-ACCESS was developed within the Marie-Josée and…